SecBot SecBot

HRTX drug pipeline

$0.2800
−9.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±6.8%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since March 2023.

APONVIE aprepitant Updated Nov 9

What to watch

APONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.

Bull case
  • APONVIE is the first and only FDA-approved IV formulation of a substance P/NK1 receptor antagonist for postoperative nausea and vomiting (PONV), a large addressable market of ~36 million annual U.S. procedures.
  • APONVIE revenue grew 49.3% YoY in Q3 2026, showing strong commercial momentum and market adoption.
  • APONVIE was included in the Fifth Consensus Guidelines for PONV management (December 2025), which should support continued adoption by hospital formularies.
Bear case
  • APONVIE faces competition from oral aprepitant (Emend) and other NK1 antagonists, as well as from generic antiemetics used in the hospital setting.
  • Heron's overall Q3 2026 revenue declined 7.8% YoY to $35.3M, and the company reported a net loss, indicating the broader business was under pressure before the asset sale.
  • The CorMedix asset sale (expected Q1 2027) means Heron shareholders will no longer directly benefit from APONVIE's future revenue growth; the upside is capped at the deal consideration.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized (FDA approved May 2021). Under the CorMedix asset purchase agreement, ZYNRELEF will transfer to CorMedix upon deal close, expected Q1 2027.

ZYNRELEF bupivacaine / meloxicam Updated Nov 9

What to watch

ZYNRELEF is now part of the asset sale to CorMedix (CRMD), expected to close in Q1 2027. For HRTX shareholders, the stock is transitioning into a stub: Heron will retain CRMD shares, net operating loss carryforwards (~$2.3B), and earn-out rights. The next event is the shareholder vote and regulatory clearance for the sale. For investors tracking ZYNRELEF specifically, watch CorMedix's commercial execution post-close and any label expansion efforts under new ownership.

Bull case
  • ZYNRELEF is an FDA-approved, differentiated non-opioid for postoperative pain, combining a local anesthetic (bupivacaine) with an NSAID (meloxicam) in an extended-release formulation that provides up to 72 hours of pain relief.
  • ZYNRELEF net revenue grew 13.8% YoY in Q3 2026, showing continued commercial uptake despite a challenging competitive landscape.
  • The non-opioid pain management market is expanding: new state laws require insurers to cover non-opioid pain meds, and the FDA approved Journavx (suzetrigine) in 2026, the first new pain-drug class in decades, raising awareness for the category.
Bear case
  • ZYNRELEF faces entrenched competition from Pacira's Exparel (bupivacaine liposome), which has a longer market history and is now being acquired by Viatris (VTRS) for $1.65B, creating a well-capitalized rival.
  • Heron's total Q3 2026 revenue fell 7.8% YoY to $35.3M, missing consensus of $37.5M, suggesting the Acute Care franchise is not gaining traction fast enough.
  • Analyst sentiment has soured: HC Wainwright downgraded to Neutral and Needham downgraded to Hold in mid-2026, with the consensus now 0 Buy, 4 Hold, 1 Sell, 2 Strong Sell.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since August 2016. Currently being sold to CorMedix as part of an asset acquisition expected to close in Q1 2027.

SUSTOL granisetron Updated Nov 9

What to watch

SUSTOL is now part of the CorMedix asset acquisition announced November 9, 2026. For HRTX shareholders, the key event is the stockholder vote on the asset sale (expected Q1 2027). For CRMD shareholders, watch for integration and potential re-commercialization of SUSTOL. There are no standalone binary catalysts for SUSTOL itself.

Bull case
  • SUSTOL is an FDA-approved extended-release granisetron injection covering both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV), a large market.
  • The drug uses Heron's proprietary Biochronomer drug-delivery technology for sustained subcutaneous release, offering a differentiated profile versus standard granisetron.
  • CorMedix is acquiring SUSTOL along with three other commercial-stage hospital products, potentially bringing better commercial resources to re-launch the product.
Bear case
  • SUSTOL commercial sales ceased on September 30, 2026, indicating the product was no longer generating meaningful revenue for Heron.
  • The drug faces intense competition from generic granisetron, oral 5-HT3 antagonists, and NK1 receptor antagonists like CINVANTI (aprepitant) and Emend.
  • As an already-approved drug with no pending label expansion or new indication, SUSTOL has no binary catalysts to drive upside.

Other drugs in filings and trials

no drug report yet
  • ZYNRELEF KIT Last: Approval · May 12, 2021
  • CINVANTI Last: Approval · Nov 9, 2017
  • Aprepitant injectable emulsion 1 trial
  • B10 L-BPA Injection 1 trial

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Sep 16, 2022APONVIEApproval−5.1%−18.3%
May 12, 2021ZYNRELEF KITApproval−15.9%−24.4%
Nov 9, 2017CINVANTIApproval−3.3%−4.7%
Aug 9, 2016SUSTOLApproval+8.5%+13.9%

Clinical trials

6 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
B10 L-BPA InjectionA Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent MeningiomaPhase 2Completed10Aug 7, 2025
ZYNRELEFPK and Safety After C-SectionPhase 2Completed · results25Dec 3, 2021
ZYNRELEFStudy of Post-Herniorrhaphy Non-opioid MMA RegimensPhase 3Completed · results209Oct 25, 2021
HTX-034 low doseDose-Escalation Study of HTX-034 Following BunionectomyPhase 2Completed · results78Jul 15, 2021
Aprepitant injectable emulsionAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)Phase 2Terminated · results27Apr 9, 2021
ZYNRELEFHTX-011 for Post-bunionectomy AnalgesiaPhase 2Completed · results71Sep 2015